These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 9784932)

  • 1. Sustained relief of chronic pain. Pharmacokinetics of sustained release morphine.
    Gourlay GK
    Clin Pharmacokinet; 1998 Sep; 35(3):173-90. PubMed ID: 9784932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of twenty-four-hourly Kapanol compared to twelve-hourly MS Contin in the treatment of severe cancer pain.
    Gourlay GK; Cherry DA; Onley MM; Tordoff SG; Conn DA; Hood GM; Plummer JL
    Pain; 1997 Feb; 69(3):295-302. PubMed ID: 9085304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine.
    Kinzler ER; Pantaleon C; Iverson M; Aigner S
    Adv Ther; 2019 Sep; 36(9):2394-2401. PubMed ID: 31278694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steady-state pharmacokinetic comparison of a new, extended-release, once-daily morphine formulation, Avinza, and a twice-daily controlled-release morphine formulation in patients with chronic moderate-to-severe pain.
    Portenoy RK; Sciberras A; Eliot L; Loewen G; Butler J; Devane J
    J Pain Symptom Manage; 2002 Apr; 23(4):292-300. PubMed ID: 11997198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of oral morphine sulfate in dogs: a comparison of sustained release and conventional formulations.
    Dohoo SE; Tasker RA
    Can J Vet Res; 1997 Oct; 61(4):251-5. PubMed ID: 9342447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients.
    Thirlwell MP; Sloan PA; Maroun JA; Boos GJ; Besner JG; Stewart JH; Mount BM
    Cancer; 1989 Jun; 63(11 Suppl):2275-83. PubMed ID: 2720576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy, safety and pharmacokinetics of a newly developed controlled release morphine sulphate suppository in patients with cancer pain.
    Moolenaar F; Meijler WJ; Frijlink HW; Visser J; Proost JH
    Eur J Clin Pharmacol; 2000 Jun; 56(3):219-23. PubMed ID: 10952476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of the route of administration: a comparative study at steady state of oral sustained release morphine and morphine sulfate suppositories.
    Du X; Skopp G; Aderjan R
    Ther Drug Monit; 1999 Apr; 21(2):208-14. PubMed ID: 10217341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relative bioavailability of morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA®) and an extended release morphine sulfate capsule formulation (KADIAN®) in healthy adults under fasting conditions.
    Johnson FK; Ciric S; Boudriau S; Kisicki JC; Stauffer J
    Am J Ther; 2011 Jan; 18(1):2-8. PubMed ID: 20864883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of Morphine Sulfate Orodispersible Tablets and Bioequivalence with Immediate-Release Oral Morphine Sulfate Formulations in Healthy Adult Subjects Under Fasting Conditions: Single-Dose Comparative Bioavailability Studies.
    Atrux-Tallau N; Naimi Z; Jaudinot EO
    Clin Drug Investig; 2022 Dec; 42(12):1101-1112. PubMed ID: 36331670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of food on the comparative pharmacokinetics of modified-release morphine tablet formulations: Oramorph SR and MST Continus.
    Drake J; Kirkpatrick CT; Aliyar CA; Crawford FE; Gibson P; Horth CE
    Br J Clin Pharmacol; 1996 May; 41(5):417-20. PubMed ID: 8735684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The United States experience with oral controlled-release morphine (MS Contin tablets). Parts I and II. Review of nine dose titration studies and clinical pharmacology of 15-mg, 30-mg, 60-mg, and 100-mg tablet strengths in normal subjects.
    Kaiko RF; Grandy RP; Oshlack B; Pav J; Horodniak J; Thomas G; Ingber E; Goldenheim PD
    Cancer; 1989 Jun; 63(11 Suppl):2348-54. PubMed ID: 2720580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic evaluations of novel oral morphine sustained release granules.
    Nakamura K; Nara E; Fuse T; Akiyama Y
    Biol Pharm Bull; 2007 Aug; 30(8):1456-60. PubMed ID: 17666803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance of the pharmacokinetic characteristics of an abuse-deterrent, extended-release, injection-molded morphine tablet.
    Dayno JM; Niebler G; Lawler J; Elhauge T; Lindhardt K
    J Opioid Manag; 2017; 13(2):111-124. PubMed ID: 28829526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steady-state pharmacokinetic evaluation of a novel, controlled-release morphine suppository and subcutaneous morphine in cancer pain.
    Bruera E; Fainsinger R; Spachynski K; Babul N; Harsanyi Z; Darke AC
    J Clin Pharmacol; 1995 Jul; 35(7):666-72. PubMed ID: 7560246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology of drugs formulated with DepoFoam: a sustained release drug delivery system for parenteral administration using multivesicular liposome technology.
    Angst MS; Drover DR
    Clin Pharmacokinet; 2006; 45(12):1153-76. PubMed ID: 17112293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioequivalence study of two morphine extended release formulations after multiple dosing in healthy volunteers.
    Heinrich-Nols J; Schug BS; Evers G; Larsimont V; Elze M; Blume HH; Lee LS; Crawford F
    Int J Clin Pharmacol Ther; 1999 Mar; 37(3):153-8. PubMed ID: 10190764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative Oral Bioavailability of an Abuse-deterrent, Extended-release Formulation of Morphine Versus Extended-release Morphine: A 2-period, Single-dose, Randomized Crossover Study in Healthy Subjects.
    Kinzler ER; Pantaleon C; Aigner S
    Clin Ther; 2018 Aug; 40(8):1357-1365. PubMed ID: 30049503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Criteria to assess in vivo performance of sustained release products: application to diltiazem formulations.
    Bialer M; Sussan S; Abu Salach O; Danenberg HD; Ben-David J; Gibor Y; Laor A
    J Pharm Sci; 1995 Oct; 84(10):1160-3. PubMed ID: 8801328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.